SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging following positive Phase 3 clinical trial results for its personalized mRNA cancer vaccine in melanoma, triggering an intense short squeeze that has captured significant market attention. While bulls are celebrating the potential platform validation and aggressive price momentum, a segment of the community remains cautious, citing concerns over future share dilution and the long timeline before potential commercial viability.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is surging as investors react to a White House crypto summit and increased Treasury bond buyback operations, triggering a massive short squeeze that liquidated over a billion dollars in bearish positions. The community is actively debating whether this breakout signals the end of the crypto winter or if it remains a temporary bull trap amidst ongoing macroeconomic uncertainty.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as investors react to strong institutional accumulation and positive momentum in TIL therapy, with the community actively discussing potential catalysts like revised revenue guidance and upcoming clinical data in lung cancer. Bulls are celebrating a breakout into new 52-week highs, leading to significant pressure on short positions and increased speculation regarding the company's long-term potential for a strategic buyout.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining momentum as investors closely track the upcoming phase two maintenance trial results, which many view as a crucial de-risking catalyst for the company's broader GLP-1/GIP pipeline. Community sentiment is increasingly focused on the potential for superior efficacy and the possibility of a strategic partnership or acquisition by major pharmaceutical players looking to challenge current market leaders.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is seeing elevated trading volume and retail investor buzz as it heads into an earnings report, with the community actively debating whether the stock will break out toward double digits or suffer a post-earnings sell-off like other fintech peers. Traders are heavily focused on the stock's consolidation near its current levels, while speculative discussion centers on potential share buybacks and future growth catalysts.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to a quarterly report featuring raised revenue guidance and progress on the Sanofi COVID-influenza combination program, though community sentiment remains divided due to the absence of new licensing deals for their proprietary combination asset. Investors are actively debating the company's long-term pivot toward a lean, partnership-driven licensing model while monitoring institutional accumulation despite the lack of immediate price momentum.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following segments: Walmart U.S., Walmart International, and Sam's Club U.S. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club U.S. segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is seeing intense options activity as traders position themselves ahead of the upcoming earnings report, with community sentiment divided between concerns over a bearish technical breakdown and bullish expectations for continued e-commerce growth. Investors are closely monitoring price action and institutional volume as they weigh potential consumer spending pressures against the company's strong retail network.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. is trending as the community reacts to a high-profile statement from the CFTC Chair and POTUS regarding plans to bring the decentralized crypto exchange Hyperliquid into the United States. Investors are aggressively discussing a potential gamma squeeze and long-term valuation upside, driven by the platform's unique fee-burning model, recent index inclusion, and a significant disconnect between the stock price and the underlying asset's rapid growth.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors speculate on a potential buyout following reports of institutional interest and persistent rumors surrounding a take-private bid. The community is actively debating the likelihood of a short squeeze, with many users urging others to hold their positions to pressure heavily shorted shares upward.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant volatility as investors react to a combination of strong interest in its personalized medicine data platform and news of a pre-planned insider stock sale. The community remains sharply divided, with bulls highlighting the stock's potential as an AI-driven healthcare leader while bears focus on short-term price pressure and concerns regarding insider selling.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HTOO $QIND - Both depend heavily on share dilution / equity raises. Neither generates positive free cash flow or profits yet. Fusion raises via its own stock (diluting HTOO holders) to fund operations, debt service, and capital injections into QIND. QIND then dilutes its own public shareholders.  
 
****It’s a classic micro-cap funding loop: revenue scaling but losses + low cash = perpetual need for fresh equity*** 
 
 
Individually they’re already high-risk (unprofitable, going-concern flags, razor-thin liquidity, pivot execution risk). Combined, the picture is worse because they’re structurally linked: 
 
QIND’s growth is now Fusion’s main revenue driver, but Fusion’s own strained balance sheet (tiny cash, huge deficit) means any hiccup in raises directly starves the sub. 
 
Dilution compounds across both tickers — Fusion holders get diluted to fund QIND, while QIND holders get diluted by the parent’s infusions.

StockTwits Web

Fusion Fuel Green PLC

Quality Industrial Corp

 - Both depend heavily on share dilution / equity raises. Neither generates positive free cash flow or profits yet. Fusion raises via its own stock (diluting HTOO holders) to fund operations, debt service, and capital injections into QIND. QIND then dilutes its own public shareholders.  
 
****It’s a classic micro-cap funding loop: revenue scaling but losses + low cash = perpetual need for fresh equity*** 
 
 
Individually they’re already high-risk (unprofitable, going-concern flags, razor-thin liquidity, pivot execution risk). Combined, the picture is worse because they’re structurally linked: 
 
QIND’s growth is now Fusion’s main revenue driver, but Fusion’s own strained balance sheet (tiny cash, huge deficit) means any hiccup in raises directly starves the sub. 
 
Dilution compounds across both tickers — Fusion holders get diluted to fund QIND, while QIND holders get diluted by the parent’s infusions.